Clinical Trial Update: 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating intravitreal injections combining triamcinolone acetonide with ranibizumab (Lucentis) for neovascular age-related macular …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Lucentis (ranibizumab)
• TRIAMCINOLONE ACETONIDE (TRIAMCINOLONE ACETONIDE)

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Age-Related Macular Degeneration, Choroidal Neovascularization | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-10-20